Linked Life Data

6254684

Source:http://linkedlifedata.com/resource/pubmed/id/6254684

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1981-2-26
pubmed:abstractText
In a phase II trial, the clinical activity of prednimustine, an ester of chlorambucil and prednisolone, was evaluated in 28 patients with small-cell anaplastic carcinoma of the lung. Prednimustine was given at dose levels ranging from 130 to 220 mg/m2/daily for 5 days every 3 weeks. Among 19 previously treated patients no responses were observed, while responses of 2, 2, and 3 months' duration were seen in three of nine previously untreated patients more than 70 years old. The toxicity took the form of mental disturbances in six patients, while the hematologic toxicity was mild. The therapeutic effectiveness of prednimustine in small-cell carcinoma of the lung is thus limited although some activity is observed in previously untreated patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0344-5704
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
259-61
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1980
pubmed:articleTitle
Phase II trial of prednimustine (NSC-134087) in the treatment of small-cell anaplastic carcinoma of the lung.
pubmed:publicationType
Journal Article